BR0311248A - Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino - Google Patents
Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico femininoInfo
- Publication number
- BR0311248A BR0311248A BR0311248-9A BR0311248A BR0311248A BR 0311248 A BR0311248 A BR 0311248A BR 0311248 A BR0311248 A BR 0311248A BR 0311248 A BR0311248 A BR 0311248A
- Authority
- BR
- Brazil
- Prior art keywords
- long
- ester
- acting
- contraception
- hrt
- Prior art date
Links
- 229960002941 etonogestrel Drugs 0.000 title abstract 6
- -1 etonogestrel ester Chemical class 0.000 title abstract 5
- 239000003098 androgen Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000002148 esters Chemical class 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000003433 contraceptive agent Substances 0.000 abstract 2
- 230000002254 contraceptive effect Effects 0.000 abstract 2
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 abstract 1
- 239000004519 grease Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077118 | 2002-05-30 | ||
| PCT/EP2003/050188 WO2003101374A2 (en) | 2002-05-30 | 2003-05-22 | Use of new etonogestrel esters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0311248A true BR0311248A (pt) | 2005-03-15 |
Family
ID=29595013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0311248-9A BR0311248A (pt) | 2002-05-30 | 2003-05-22 | Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20050222114A1 (enExample) |
| EP (1) | EP1513588B1 (enExample) |
| JP (1) | JP2005532336A (enExample) |
| KR (1) | KR20050005507A (enExample) |
| CN (1) | CN1655848A (enExample) |
| AR (1) | AR040129A1 (enExample) |
| AT (1) | ATE394140T1 (enExample) |
| AU (1) | AU2003246740B2 (enExample) |
| BR (1) | BR0311248A (enExample) |
| CA (1) | CA2487293A1 (enExample) |
| DE (1) | DE60320786D1 (enExample) |
| ES (1) | ES2305498T3 (enExample) |
| HR (1) | HRP20041127A2 (enExample) |
| IL (1) | IL165125A0 (enExample) |
| IS (1) | IS7537A (enExample) |
| MX (1) | MXPA04011798A (enExample) |
| NO (1) | NO20044903L (enExample) |
| NZ (1) | NZ536618A (enExample) |
| PE (1) | PE20040042A1 (enExample) |
| PL (1) | PL373295A1 (enExample) |
| RS (1) | RS101004A (enExample) |
| RU (1) | RU2322986C2 (enExample) |
| TW (1) | TW200400041A (enExample) |
| UA (1) | UA80703C2 (enExample) |
| WO (1) | WO2003101374A2 (enExample) |
| ZA (1) | ZA200409498B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200403065A (en) * | 2002-05-30 | 2004-03-01 | Akzo Nobel Nv | New etonogestrel esters |
| US20130123523A1 (en) * | 2011-11-10 | 2013-05-16 | Klaus Nickisch | Methods for the preparation of etonogestrel and desogestrel |
| DE102012211511A1 (de) * | 2012-07-03 | 2014-01-09 | Siemens Aktiengesellschaft | Bestimmung der Eignung einer Ressource |
| MX2020003470A (es) * | 2017-10-19 | 2020-10-01 | Evestra Inc | Anticonceptivos de profarmacos de progestina de accion mas prolongada. |
| CN111057120B (zh) * | 2019-12-27 | 2021-04-27 | 苏州翔实医药发展有限公司 | 一种依托孕烯衍生物a及其制备方法和用途 |
| WO2021252761A2 (en) * | 2020-06-11 | 2021-12-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227989A1 (de) * | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
| DE4240806A1 (de) * | 1992-12-01 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol |
| JPH07101884A (ja) * | 1993-10-01 | 1995-04-18 | Sanei Gen F F I Inc | 水溶性ヘミセルロースを含有する製剤 |
| CZ187796A3 (en) * | 1993-12-27 | 1997-01-15 | Akzo Nobel Nv | Pharmaceutical preparation |
| JPH11509222A (ja) * | 1995-07-17 | 1999-08-17 | シェリング アクチェンゲゼルシャフト | １３−エチル−１７β−ヒドロキシ−１１−メチレン−１８，１９−ジノル−１７α−プレグン−４−エン−２０−イン−３−オンのエステルを含む経皮投与のための剤 |
| CA2333985C (en) * | 1998-06-19 | 2007-04-10 | Dirk Leysen | Testosterone derivative |
| WO1999067270A1 (en) * | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) |
| US6180682B1 (en) * | 1999-01-26 | 2001-01-30 | Virgil A. Place | Buccal drug delivery system for use in male contraception |
| TW200403065A (en) * | 2002-05-30 | 2004-03-01 | Akzo Nobel Nv | New etonogestrel esters |
-
2003
- 2003-05-19 TW TW092113492A patent/TW200400041A/zh unknown
- 2003-05-22 CN CNA038123657A patent/CN1655848A/zh active Pending
- 2003-05-22 US US10/517,362 patent/US20050222114A1/en not_active Abandoned
- 2003-05-22 KR KR10-2004-7019327A patent/KR20050005507A/ko not_active Withdrawn
- 2003-05-22 HR HR20041127A patent/HRP20041127A2/hr not_active Application Discontinuation
- 2003-05-22 PL PL03373295A patent/PL373295A1/xx not_active Application Discontinuation
- 2003-05-22 AT AT03755980T patent/ATE394140T1/de not_active IP Right Cessation
- 2003-05-22 EP EP03755980A patent/EP1513588B1/en not_active Expired - Lifetime
- 2003-05-22 UA UA20041109285A patent/UA80703C2/uk unknown
- 2003-05-22 BR BR0311248-9A patent/BR0311248A/pt not_active IP Right Cessation
- 2003-05-22 DE DE60320786T patent/DE60320786D1/de not_active Expired - Fee Related
- 2003-05-22 RS YU101004A patent/RS101004A/sr unknown
- 2003-05-22 AU AU2003246740A patent/AU2003246740B2/en not_active Ceased
- 2003-05-22 CA CA002487293A patent/CA2487293A1/en not_active Abandoned
- 2003-05-22 WO PCT/EP2003/050188 patent/WO2003101374A2/en not_active Ceased
- 2003-05-22 RU RU2004138809/15A patent/RU2322986C2/ru active
- 2003-05-22 MX MXPA04011798A patent/MXPA04011798A/es unknown
- 2003-05-22 JP JP2004508732A patent/JP2005532336A/ja not_active Withdrawn
- 2003-05-22 ES ES03755980T patent/ES2305498T3/es not_active Expired - Lifetime
- 2003-05-22 NZ NZ536618A patent/NZ536618A/en unknown
- 2003-05-26 PE PE2003000508A patent/PE20040042A1/es not_active Application Discontinuation
- 2003-05-28 AR ARP030101858A patent/AR040129A1/es unknown
-
2004
- 2004-11-09 IL IL16512504A patent/IL165125A0/xx unknown
- 2004-11-10 NO NO20044903A patent/NO20044903L/no not_active Application Discontinuation
- 2004-11-18 IS IS7537A patent/IS7537A/is unknown
- 2004-11-24 ZA ZA200409498A patent/ZA200409498B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2487293A1 (en) | 2003-12-11 |
| IL165125A0 (en) | 2005-12-18 |
| ZA200409498B (en) | 2006-05-31 |
| AU2003246740A1 (en) | 2003-12-19 |
| EP1513588A2 (en) | 2005-03-16 |
| ES2305498T3 (es) | 2008-11-01 |
| DE60320786D1 (de) | 2008-06-19 |
| AR040129A1 (es) | 2005-03-16 |
| RU2322986C2 (ru) | 2008-04-27 |
| IS7537A (is) | 2004-11-18 |
| CN1655848A (zh) | 2005-08-17 |
| PL373295A1 (en) | 2005-08-22 |
| RS101004A (sr) | 2006-10-27 |
| RU2004138809A (ru) | 2005-06-10 |
| WO2003101374A2 (en) | 2003-12-11 |
| US20050222114A1 (en) | 2005-10-06 |
| NO20044903L (no) | 2005-02-25 |
| HK1072568A1 (en) | 2005-09-02 |
| MXPA04011798A (es) | 2005-03-31 |
| HRP20041127A2 (en) | 2005-02-28 |
| JP2005532336A (ja) | 2005-10-27 |
| ATE394140T1 (de) | 2008-05-15 |
| PE20040042A1 (es) | 2004-01-31 |
| TW200400041A (en) | 2004-01-01 |
| EP1513588B1 (en) | 2008-05-07 |
| NZ536618A (en) | 2007-06-29 |
| KR20050005507A (ko) | 2005-01-13 |
| UA80703C2 (en) | 2007-10-25 |
| WO2003101374A3 (en) | 2004-02-26 |
| AU2003246740B2 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0311254A (pt) | Composto, kit contraceptivo e/ou de hrt, uso de uma quantidade contraceptiva e/ou terapeuticamente eficaz de um composto, e, métodos de contracepção e/ou hrt, e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino | |
| TR200200706T2 (tr) | Nöropatik ağrı tedavisi için retigabin kullanımı. | |
| EP1377245A4 (en) | IMMUNOSTIMULATING COATING FOR SURGICAL DEVICES | |
| BR0314016A (pt) | Dispositivo para incontinência urinária intravaginal e método de alìvio de incontinência urinária feminina | |
| FR2804010B1 (fr) | Dispositif percutane pour le traitement de l'incontinence urinaire d'effort de la femme par bandelette sous uretrale | |
| EP0951887A3 (en) | Absorbent article | |
| WO2005007112A3 (en) | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration | |
| AU9177501A (en) | Novel testosterone ester formulation for human use | |
| GR3034575T3 (en) | Steroid nitrite ester derivatives useful as anti-inflammatory drugs | |
| BR0311248A (pt) | Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino | |
| ZA200104923B (en) | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease. | |
| DK79493D0 (da) | Eksternt urinkateter | |
| WO2006042021A3 (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| IL155174A0 (en) | Methods and compositions for the treatment of inflammatory diseases | |
| BRPI0318195B8 (pt) | método para fabricar um preservativo feminino e preservativo feminino | |
| BR9915664A (pt) | Estrutura de anel dessensibilizador | |
| BR0313589A (pt) | Uso de extrato de germe de trigo fermentado como agente antiinflamatório | |
| BR9814136A (pt) | Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto. | |
| DE602004018921D1 (de) | D dienogest | |
| HUP0300128A3 (en) | Male contraceptive composition comprising norethisterone and its use | |
| WO2003099322A3 (en) | Il-11 derivatives and therapeutic uses thereof | |
| BR0213634A (pt) | Sistema de liberação de droga com ação retardada para um agente antiespasmódico | |
| HUP0200354A3 (en) | Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases | |
| GB2411836B (en) | Condom with male genital desensitizer lubricant | |
| GB0030580D0 (en) | Composition and method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: N.V. ORGANON (NL) Free format text: TRANSFERIDO DE: AKZO NOBEL N.V. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 7A. E 8A. ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES. |